Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
80M
-
Number of holders
-
253
-
Total 13F shares, excl. options
-
92.1M
-
Shares change
-
+5.97M
-
Total reported value, excl. options
-
$4.92B
-
Value change
-
+$352M
-
Put/Call ratio
-
0.5
-
Number of buys
-
140
-
Number of sells
-
-127
-
Price
-
$53.36
Significant Holders of Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) as of Q2 2025
325 filings reported holding AKRO - Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) has 253 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 92.1M shares
.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (6.74M shares), BlackRock, Inc. (5.78M shares), GENERAL ATLANTIC, L.P. (5.73M shares), RTW INVESTMENTS, LP (5.48M shares), VANGUARD GROUP INC (4.53M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.51M shares), Avoro Capital Advisors LLC (3.5M shares), WELLINGTON MANAGEMENT GROUP LLP (3.41M shares), Deep Track Capital, LP (3.04M shares), and STATE STREET CORP (2.75M shares).
This table shows the top 253 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.